Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

Takeda Pharmaceutical's AI-developed drug zasocitinib demonstrated statistical superiority over Bristol-Myers Squibb's deucravacitinib in a Phase 3 head-to-head trial for plaque psoriasis treatment. Zasocitinib achieved over 35% complete skin clearance (PASI 100) at week 16, more than 2.5 times the response rate of the competitor drug. The company plans to submit a New Drug Application to the FDA this fiscal year, with peak annual sales potential of $3-6 billion.

06/11/2026, 1:12 PM • Benzinga

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Ascentage Pharma presented updated clinical data at ASCO 2026 showing olverembatinib achieved a 91.3% complete cytogenetic response rate and 60.9% major molecular response rate at cycle 24 in CML-CP patients as second-line therapy. The drug demonstrated a stable safety profile with no new safety signals, supporting its potential role in treating patients who failed first-line TKI therapy.

05/31/2026, 7:30 PM • GlobeNewswire

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Ascentage Pharma announced Phase Ib study results showing olverembatinib combined with blinatumomab demonstrated encouraging clinical activity in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP, with 91% achieving complete response and manageable safety profile. The company presented six studies across three key assets at the 2026 ASCO Annual Meeting, marking its ninth consecutive appearance.

05/31/2026, 7:30 PM • GlobeNewswire

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

05/25/2026, 5:31 AM • GlobeNewswire

Jury Hits Takeda With $885 Million Antitrust Verdict

A Massachusetts jury awarded $884.9 million in damages against Takeda Pharmaceutical in an antitrust case related to its constipation drug Amitiza. The verdict stems from allegations that a 2014 settlement agreement between Takeda, Sucampo Pharmaceuticals, and Par Pharmaceutical delayed generic competition. The damages will automatically triple under U.S. antitrust law once judgment is entered. Takeda plans to appeal, defending the settlement as compliant with pharmaceutical patent dispute regulations.

05/19/2026, 1:48 PM • Benzinga

Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight

The global stem cell therapy market is projected to grow from USD 21.9 billion in 2025 to USD 58.5 billion by 2034, driven by technological advancements, favorable regulations, and rising demand for regenerative medicine treatments for chronic diseases. North America leads the market with 48.87% share, while Asia-Pacific emerges as a key growth engine with recent approvals of iPSC-based therapies in Japan.

05/05/2026, 1:00 PM • GlobeNewswire

IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight

The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.

04/29/2026, 1:00 PM • GlobeNewswire

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight

The polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.

04/22/2026, 1:00 PM • GlobeNewswire

Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight

Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

04/16/2026, 1:00 PM • GlobeNewswire

The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.

04/14/2026, 1:00 PM • GlobeNewswire

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.

04/13/2026, 1:00 PM • GlobeNewswire

Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

04/10/2026, 4:43 AM • GlobeNewswire

Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

Takeda Pharmaceutical has terminated its collaboration with Denali Therapeutics on DNL593, a progranulin replacement therapy for frontotemporal dementia. The decision is strategic and not related to safety or efficacy concerns. Denali regains full ownership and control of the therapy, with plans to report Phase 1/2 trial results by end of 2026. Denali shares fell 3.73% on the news.

04/06/2026, 1:26 PM • Benzinga

What's Going On With Eli Lilly On Monday?

Eli Lilly announced a $3 billion investment in China over the next decade, with its obesity drug Mounjaro added to China's state health insurance reimbursement list. However, the company faces a setback as the U.S. Supreme Court allowed a multibillion-dollar class action lawsuit to proceed against Eli Lilly and Takeda Pharmaceutical regarding inadequate risk disclosures for the diabetes drug Actos. LLY shares were up 0.75% at $913.46.

03/23/2026, 1:20 PM • Benzinga

Feiba VH (Takeda Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F

A market research report projects growth in the Feiba VH market through 2035, driven by increasing hemophilia diagnoses, rising healthcare expenditure, expanding surgical procedures, and personalized hemophilia management. North America leads the market while Asia-Pacific is expected to experience the fastest growth. Tariffs are influencing costs but encouraging domestic investment in coagulation therapies.

03/10/2026, 8:00 AM • GlobeNewswire